Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Charles River Laboratories International, Inc.

Market Cap 8.91B 7.77B 7.2B 6.74B 12.63B 841B 12.71B 85.37B 33.08B 414B 33.45B 32.73B 1,437B P/E 2026 *
30.2x
P/E 2027 * 20.2x
Enterprise Value 10.72B 9.35B 8.66B 8.11B 15.2B 1,012B 15.29B 103B 39.81B 498B 40.25B 39.39B 1,729B EV / Sales 2026 *
2.78x
EV / Sales 2027 * 2.64x
Free-Float
97%
Yield 2026 *
-
Yield 2027 * -
Jun. 18 Charles River Laboratories International, Inc. and Eli Lilly and Company Enter Collaboration to Optimize Ai/Ml Platform Through Nonclinical Testing Expertise CI
Jun. 18 Rothschild & Co Redburn Adjusts Charles River Laboratories International PT to $241 From $230, Maintains Buy Rating MT
Jun. 17 Charles River Laboratories Shares Rise After Morgan Stanley Upgrade MT
Jun. 17 Morgan Stanley Upgrades Charles River Laboratories International to Overweight From Equal Weight, Adjusts PT to $220 From $185 MT
Jun. 05 Charles River Laboratories Has Potential to Outperform in 2H 2026, RBC Says MT
Jun. 03 Charles River Laboratories International, Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-03-2026 09:55 AM
Jun. 02 Charles River Laboratories International, Inc. Presents at 46th Annual William Blair Growth Stock Conference, Jun-02-2026 10:00 AM
May. 13 Charles River Laboratories, Medipost Sign MoU on GMP-Compliant Testing MT
May. 13 Charles River Laboratories and Medipost sign non-exclusive MoU to advance GMP testing solutions RE
May. 13 Charles River Laboratories and MEDIPOST Co., Ltd. Sign Non-Exclusive MOU to Collaborate on GMP-Compliant Testing and Commercial and Marketing Efforts CI
May. 11 Charles River Laboratories International, Inc. Approves Ratification of PricewaterhouseCoopers LLP as Independent Auditors CI
May. 11 Charles River Laboratories International, Inc. Announces Board Elections CI
May. 11 Charles River Laboratories International, Inc. Accelerates Digital Pathology with Ai-Powered End-To-End Workflow CI
1 month 148.34
Extreme 148.335
148.34
Current year 148.34
Extreme 148.335
148.34
1 year 148.34
Extreme 148.335
148.34
3 years 148.34
Extreme 148.335
148.34
5 years 148.34
Extreme 148.335
148.34
10 years 148.34
Extreme 148.335
148.34
Manager TitleAgeSince
Chief Executive Officer 56 2026-05-04
Director of Finance/CFO 58 2026-04-05
Chief Tech/Sci/R&D Officer 45 2026-01-11
Director TitleAgeSince
Chairman 75 1999-12-31
Director/Board Member 56 2026-05-04
Chairman 69 2026-05-04
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 8.91B
+1.44%+1.71%-10.98%-5.59% 43.13B
+3.31%+5.93%+310.97%+532.23% 34.65B
+2.84%+2.14%+9.34%+45.55% 30.03B
-1.70%-7.54%+8.43%-21.54% 28B
-1.90%-1.56%+10.24%+22.81% 24.45B
-0.14%+5.86% - - 14.34B
+0.68%-1.53%+48.76%+108.76% 13.14B
-0.57%-2.43%+5.08%+6.76% 12.53B
-0.26%+1.15%+98.13%+79.60% 12.25B
Average +0.37%+0.73%+60.00%+96.07% 23.61B
Weighted average by Cap. +0.74%+1.27%+65.47%+111.07%

Financials

2026 *2027 *
Net sales 3.85B 3.36B 3.11B 2.91B 5.46B 364B 5.49B 36.91B 14.3B 179B 14.46B 14.15B 621B 3.92B 3.42B 3.17B 2.97B 5.56B 370B 5.6B 37.59B 14.57B 182B 14.73B 14.41B 633B
Net income 285M 249M 230M 216M 404M 26.9B 407M 2.73B 1.06B 13.24B 1.07B 1.05B 45.98B 417M 364M 337M 315M 592M 39.38B 595M 4B 1.55B 19.38B 1.57B 1.53B 67.3B
Net Debt 1.81B 1.58B 1.46B 1.37B 2.57B 171B 2.58B 17.36B 6.73B 84.17B 6.8B 6.66B 292B 1.46B 1.28B 1.18B 1.11B 2.08B 138B 2.09B 14.03B 5.44B 68.04B 5.5B 5.38B 236B
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
19,000
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
185.00USD
Average target price
215.33USD
Spread / Average Target
+16.40%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!